Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Hodgkin's Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    587 result(s) found for: Non-Hodgkin's Lymphoma. Displaying page 16 of 30.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2009-010017-72 Sponsor Protocol Number: version 1 Start Date*: 2009-06-10
    Sponsor Name:GOELAMS
    Full Title: Bendamustine in patients with refractory or relapsed T-cell lymphoma. A phase II multicenter study “BENTLY”
    Medical condition: Lymphome T refractaire ou en rechute
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025632 Malignant lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022036-36 Sponsor Protocol Number: A8641014 Start Date*: 2011-02-15
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma
    Medical condition: advanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066110 LLT
    9.1 10065252 LLT
    9.1 10065923 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001118-14 Sponsor Protocol Number: ML28943 Start Date*: 2013-10-17
    Sponsor Name:Roche Farma, S.A.
    Full Title: Ensayo Clínico Fase IIIb abierto no-controlado para evaluar la seguridad del cambio de rituximab intravenoso a rituximab subcutáneo durante el tratamiento de primera línea de Linfoma No-Hodgkin Fol...
    Medical condition: Linfoma no-Hodgkin difuso de células B grandes CD20+ o linfoma no- Hodgkin folicular CD20+ grado 1, 2 o 3a.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061170 Follicle centre lymphoma, follicular grade I, II, III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004688-19 Sponsor Protocol Number: MOR208C203 Start Date*: 2015-10-02
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphom...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) HU (Completed) DE (Completed) ES (Ongoing) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000615-99 Sponsor Protocol Number: 00465 Start Date*: 2006-12-28
    Sponsor Name:University Medical Center Freiburg
    Full Title: Freiburger ZNS-NHL Studie Therapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation
    Medical condition: primary Non-Hodgkin Lymphoma of the Central Nervous System (PCNSL), histologically confirmed Age: 18 - 65 years
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029614 Non-Hodgkin's lymphoma unspecified histology aggressive stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003466-13 Sponsor Protocol Number: GMALL082013 Start Date*: 2015-09-15
    Sponsor Name:Goethe University Frankfurt
    Full Title: Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a ...
    Medical condition: Newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma Age 18 to 55 y
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065923 Lymphoblastic lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004474-26 Sponsor Protocol Number: FIL_PREVID Start Date*: 2020-08-12
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III s...
    Medical condition: Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000128-22 Sponsor Protocol Number: FLIRT Start Date*: 2014-11-26
    Sponsor Name:LYSARC
    Full Title: A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
    Medical condition: Stage II-IV follicular lymphoma grade 1-3a not previously treated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003716-12 Sponsor Protocol Number: C34004 Start Date*: 2017-07-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005218-19 Sponsor Protocol Number: DSHNHL2004-3 Start Date*: 2007-10-12
    Sponsor Name:German High Grade Non-Hodgkin's Lymphoma group
    Full Title: Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin,...
    Medical condition: Patients with untreated aggressive CD20+ Non-Hodgkin’s Lymphoma aged 18 to 60 years without major accompanying diseases with IPI= 1 (all) or IPI= 0 and bulky disease (≥7.5cm
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002654-21 Sponsor Protocol Number: RHMCAN1219 Start Date*: 2017-11-23
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.
    Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001748-36 Sponsor Protocol Number: GCT3013-01 Start Date*: 2018-09-24
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
    Medical condition: Relapsed, progressive and/or refractory mature B-cell lymphoma Patients with: - Diffuse large B-cell lymphoma – de novo or transformed - High-grade B-cell lymphoma - Primary mediastinal large B...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003888-23 Sponsor Protocol Number: 09/2005/2007 Start Date*: 2006-03-23
    Sponsor Name:University College London
    Full Title: A phase II multicentre trial of CVP, rituximab and gemcitabine for the treatment of patients with newly diagnosed diffuse large b-cell lymphoma considered unsuitable for r-chop chemotherapy
    Medical condition: Large B cell non-Hodgkin’s lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002625-38 Sponsor Protocol Number: ADCT-402-103 Start Date*: 2018-12-11
    Sponsor Name:ADC Therapeutics SA
    Full Title: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
    Medical condition: Diffuse large B-Cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001697-17 Sponsor Protocol Number: R1979-ONC-1504 Start Date*: 2015-12-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 monoclonal antibody, in Patients wit...
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026945 Mature B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067184 Burkitt's leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003890 B precursor type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2015-003554-41 Sponsor Protocol Number: UTA2-1DC Start Date*: 2016-03-15
    Sponsor Name:VU University Medical Center
    Full Title: A phase I/II “minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor ...
    Medical condition: Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), non Hodgkin lymphoma (nHL)(any grade), Hodgkin’s lymphoma (HL).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10020309 Hodgkin's disease, unspecified type LLT
    18.1 100000004864 10066703 Non-Hodgkin's lymphoma progression LLT
    18.1 100000004864 10028228 Multiple myeloma LLT
    18.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004516-51 Sponsor Protocol Number: GEN112 Start Date*: 2006-11-20
    Sponsor Name:Genmab A/S
    Full Title: A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Medical condition: CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001353-17 Sponsor Protocol Number: SPC2996-107 Start Date*: 2008-11-05
    Sponsor Name:Santaris Pharma A/S
    Full Title: A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA
    Medical condition: Follicular Lymphoma (FL); Lymphoplasmacytic (lymphoplasmacytoid) Lymphoma (LPL) / Waldenstrom’s macroglobulinemia (WM)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016905 Follicle centre lymphoma, follicular grade I, II, III recurrent LLT
    9.1 10025334 Lymphoplasmacytic type lymphoma (Kiel Classification) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001270-34 Sponsor Protocol Number: RIMAL1 Start Date*: 2021-04-19
    Sponsor Name:Radboud University Medical Centre
    Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system).
    Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004898-63 Sponsor Protocol Number: FIL_Copa-RB Start Date*: 2020-08-18
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Copanlisib in combination with Rituximab-Bendamustine in patients with Relapsed-Refractory Diffuse Large B-cell Lymphoma: a multicentric Phase II trial
    Medical condition: Patients with Relapsed-Refractory Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 23:12:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA